Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Roderburg

Showing results (291-300 of 295) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 295 results.
Journal of Experimental & Clinical Cancer Research : CR|November 8, 2024
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapyJoao Gorgulho, Sven H Loosen, Ramsha Masood, et al.
Cancers|March 28, 2025
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter StudyChristian Möhring, Moritz Berger, Farsaneh Sadeghlar, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Immunity|June 17, 2023
Sublethal necroptosis signaling promotes inflammation and liver cancerMihael Vucur, Ahmed Ghallab, Anne T Schneider, et al.
JHEP Reports : Innovation in Hepatology|March 1, 2021
Assessing the impact of COVID-19 on liver cancer management (CERO-19)Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.
Pageof 30

Showing results (291-300 of 295) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 295 results.
Journal of Experimental & Clinical Cancer Research : CR|November 8, 2024
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapyJoao Gorgulho, Sven H Loosen, Ramsha Masood, et al.
Cancers|March 28, 2025
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter StudyChristian Möhring, Moritz Berger, Farsaneh Sadeghlar, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Immunity|June 17, 2023
Sublethal necroptosis signaling promotes inflammation and liver cancerMihael Vucur, Ahmed Ghallab, Anne T Schneider, et al.
JHEP Reports : Innovation in Hepatology|March 1, 2021
Assessing the impact of COVID-19 on liver cancer management (CERO-19)Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.
Pageof 30